- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04932629
To Evaluate the Clinical Safety and Efficacy of Limbal Stem Cell for Treatment of Superficial Corneal Pathologies".
A Proof of Concept Study to Evaluate the Clinical Safety and Efficacy of Ex-vivo Cultivated Allogenic Limbal Stem Cell Transplantation for Treatment of Superficial Corneal Pathologies".
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This would be a single-center prospective, open labeled, non-randomized interventional study. This study is an Investigator Initiated Study (IIS). The Ethics Committee of the LV Prasad Eye Institute, Hyderabad, would prospectively approve this study. This study would be conducted in strict adherence to the tenets of the Declaration of Helsinki, ICH GCP E6 (R2), Indian GCP Guidelines and New Drugs and Clinical Trial Rules 2019 and associated amendments and current National Ethical Guidelines for Biomedical and Health Research Involving Human Participants and Current National Stem Cell Research Guidelines and New Drugs and Clinical Trial Rules 2019.
Once the participants are found to be suitable for limbal transplant surgery, the patients will be administered written informed consent and audio /visual consent as per regulations. Detailed ophthalmic examination will be done to ensure that the patient is eligible for the trial.
All the screening procedures will be accomplished within 14± 7days. On Day 0 that is the date of surgery a Unique Participant Identification Number (UPIN) will be assigned to each patient and it would be in addition to hospital medical record number. The surgery will be done under local or general anesthesia (depending on age and patient preference).
In this prospective interventional study patients with unilateral superficial corneal scars will undergo a surgical procedure. Limbal ring from a cadaveric donor tissue, which is therapeutically accepted and serologically tested, is collected. This tissue will then be cultivated in the stem cell biology laboratory using standardized culture technique. Briefly the limbal tissue will be cut up into small pieces and digested overnight using an enzyme (Collagenase L). The cells obtained from the digest will be cultured on a petri-dish using 2% serum and growth factors. The cultured cells will be passaged three times to remove all epithelial cells from the culture.
In the second procedure, the eligible patients will undergo corneal transplant surgery, when the central corneal epithelium will be removed using a surgical sponge. 0.1ml of stromal cells in a concentration of 0.5x106 cells/µl diluted in the thrombin component of fibrin glue (TISEEL, Baxter) will be applied to the debrided corneal stroma. A soft bandage contact lens will be placed over the cornea at the end of the procedure. The patient will receive topical antibiotic and steroid eye drops in the post-operative period. Periodic comprehensive ophthalmic evaluation along with anterior segment optical coherence tomography (ASOCT) scanning and slit-lamp photography will be done at Day 1, Day 7, Day 30, Day 90, Day 180 and Day 360 and 720 Days post-surgery. The primary outcome measure of this study is to note any ocular or systemic adverse effects of this intervention at the various post-operative time points. The secondary outcome measures are visual improvement and change in the density and appearance of the corneal scarring and other pathologies after treatment.
Study Type
Enrollment (Anticipated)
Phase
- Early Phase 1
Contacts and Locations
Study Contact
- Name: Dr.Sayan Basu, MBBS,MS
- Phone Number: 040-68102534
- Email: sayanbasu@lvpei.org
Study Contact Backup
- Name: Dr.Vivek Singh, PhD
- Phone Number: 040-68102286
- Email: viveksingh@lvpei.org
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male and female participants who are ≥18 and ≤ 60 years of age.
- Patients having unilateral superficial corneal pathologies (defined as involving the anterior 200µM of the corneal stroma on ASOCT imaging)
- Corneal burns, ulcers and scars
- No prior history of corneal transplantation
- No ongoing and other active ocular pathology
- Candidate for stem cell transplant
- No severe pathological and psychological conditions that might interfere with the patient's participation in the study
- Able to provide written and audio-visual informed consent prior to any study specific screening procedures with the understanding that the patient has the right to withdraw from the study at any time, for any reason without prejudice
Exclusion Criteria:
- Bilateral corneal disease,
- Corneal scars with limbal dysfunction (clinically defined as absent limbal palisades or conjunctivalization of the cornea)
- Ocular surface disease including dry eye disease (defined as a Schirmer's test of less than 10mm at 5 minutes),
- Unknown etiology, post-herpetic eye disease or eyes with active intra-ocular inflammation,
- Children (<18 years of age),
- Less than 3 months after documented clinical resolution of acute disease
- Inability/refusal to give written informed consent
- Undergo any of the anterior segment imaging tests.
- Patient should have not participated in another clinical study within 30 days of their enrolment on this study.
- History or evidence of cardiac disease: congestive heart failure; New York Heart Association (NYHA) class 2 or greater (see Appendix 6); active coronary artery disease; unstable angina, cardiac arrhythmias requiring anti-arrhythmic therapy, atrio-ventricular block of second or third degree, or uncontrolled hypertension, patients with recent (less than 6 months) myocardial infarction (MI) or coronary revascularization.
- Pregnant and lactating patients, positive urine pregnancy test in women of childbearing potential
- Reproductive age patients not practicing effective and adequate birth control measures
- Previous participation in this study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Experimental Group
The eligible patients will undergo corneal transplant surgery, when the central corneal epithelium will be removed using a surgical sponge.
0.1ml of stromal cells in a concentration of 0.5x106 cells/µl diluted in the thrombin component of fibrin glue (TISEEL, Baxter) will be applied to the debrided corneal stroma.
|
n this prospective intervention study patients with unilateral superficial corneal scars will undergo a surgical procedure and in the second procedure, the eligible patients will undergo corneal transplant surgery, when the central corneal epithelium will be removed using a surgical sponge.
0.1ml of stromal cells in a concentration of 0.5x10*6 cells/µl diluted in the thrombin component of fibrin glue (TISEEL, Baxter) will be applied to the debrided corneal stroma.
A soft bandage contact lens will be placed over the cornea at the end of the procedure.
The patient will receive topical antibiotic and steroid eye drops in the post-operative period.
Periodic comprehensive ophthalmic evaluation along with anterior segment optical coherence tomography (ASOCT) scanning and slit-lamp photography will be done at Day 1, Day 7, Day 30, Day 90, Day 180 and Day 360 and 720 Days post-surgery
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Measurement of any ocular or systemic adverse effects
Time Frame: Day 90 post-surgery
|
The primary outcome measure of this study is to note any ocular or systemic adverse effects
|
Day 90 post-surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Measurement of Visual improvement
Time Frame: Day 720 post surgery
|
Visual improvement using ETDRS vision chart method where visual acuity is the measurement, Changes in ETDRS score is a scale and ETDRS letter score will be measure in log units
|
Day 720 post surgery
|
Change in Corneal light scattering
Time Frame: Day 720 post surgery
|
Change in Corneal light scattering using Scheimpflug imaging where Corneal light scattering is the measurement, Corneal Densitometry measurements is a scale and expressed in standardized grayscale units (GSU).
|
Day 720 post surgery
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Dr.Vivek Singh, PhD, LV Prasad Eye Institute (Hyderabad Eye Research Foundation)
- Principal Investigator: Dr.Sayan Basu, MBBS.MS, LV Prasad Eye Institute (Hyderabad Eye Research Foundation)
Publications and helpful links
General Publications
- Basu S, Hertsenberg AJ, Funderburgh ML, Burrow MK, Mann MM, Du Y, Lathrop KL, Syed-Picard FN, Adams SM, Birk DE, Funderburgh JL. Human limbal biopsy-derived stromal stem cells prevent corneal scarring. Sci Transl Med. 2014 Dec 10;6(266):266ra172. doi: 10.1126/scitranslmed.3009644.
- Basu S, Damala M, Singh V. Limbal Stromal Stem Cell Therapy for Acute and Chronic Superficial Corneal Pathologies: Early Clinical Outcomes of The Funderburgh Technique. Investigative Ophthalmology & Visual Science. 2017 Jun 23;58(8):3371-337
- Funderburgh, J., Basu, S., Damala, M., Tavakkoli, F., Sangwan, V., & Singh, V. (2018). Limbal stromal stem cell therapy for acute and chronic superficial corneal pathologies: one-year outcomes. Investigative Ophthalmology & Visual Science, 59(9), 3455-3455
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HERF-SSC-SCP-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Corneal Scars and Opacities
-
L.V. Prasad Eye InstituteUnknownCorneal Scars and OpacitiesIndia
-
L.V. Prasad Eye InstituteUnknownCorneal Injuries | Corneal Scars and Opacities | Corneal BurnsIndia
-
Oregon Health and Science UniversityNational Eye Institute (NEI); National Institutes of Health (NIH)Completed
-
Oregon Health and Science UniversityNational Eye Institute (NEI)RecruitingCorneal Opacities (Scar and Stromal Dystrophy)United States
-
Carl Zeiss Meditec AGNot yet recruitingCataract | Corneal Astigmatism | Corneal Defect | Corneal Deformity | Lens Opacities | Artificial Lens Implant
-
Claris Biotherapeutics, Inc.RecruitingCorneal ScarUnited States
-
IBSA Farmaceutici Italia SrlDerming SRLCompletedAcne Scars - Mixed Atrophic and Hypertrophic | Ice Pick Scars | Rolling Scars | Boxcar ScarsItaly
-
Cynosure, Inc.Terminated
-
Boston SightEYEdeal scanning, LTCCompletedDry Eye Syndromes | Keratoconjunctivitis Sicca | Keratoconus | Sjogren's Syndrome | Ocular Surface Disease | Ectasia | Pellucid Marginal Corneal Degeneration | Corneal Trauma | Corneal ScarUnited States
-
Innovative MedicalCompleted
Clinical Trials on Ex-vivo cultivated Allogeneic limbal stromal stem cells
-
L.V. Prasad Eye InstituteUnknownCorneal Injuries | Corneal Scars and Opacities | Corneal BurnsIndia
-
Nationwide Children's HospitalCompletedOsteogenesis Imperfecta Type III | Osteogenesis Imperfecta Type IIUnited States
-
Institute of Hematology & Blood Diseases HospitalCancer Institute and Hospital, Chinese Academy of Medical Sciences; Beijing...RecruitingNon-Hodgkin's Lymphoma (NHL) | Peripheral T Cell Lymphoma (PTCL)China
-
Beijing 302 HospitalCancer Institute and Hospital, Chinese Academy of Medical Sciences; Beijing...UnknownHepatocellular CarcinomaChina
-
Massachusetts Eye and Ear InfirmaryDana-Farber Cancer InstituteCompletedLimbal Stem Cell DeficiencyUnited States
-
King Edward Medical UniversityUnknownLipodystrophy | Craniofacial Microsomia | Mixed Connective Tissue Disease | Romberg's Disease
-
Institute of Oncology LjubljanaUniversity Medical Centre Ljubljana; University of Ljubljana; Blood Transfusion...Not yet recruitingXerostomia Following RadiotherapySlovenia
-
Rigshospitalet, DenmarkActive, not recruitingMesenchymal Stem Cells | Xerostomia | Salivary Gland Diseases | Oropharynx Cancer | Hyposalivation | Dry Mouth | Mesenchymal Stromal Cells | Xerostomia Due to Radiotherapy | Stem CellsDenmark
-
Supergenics Life Science Sdn. Bhd.Not yet recruitingDiabetic Foot Ulcer
-
Uppsala UniversityUppsala University HospitalActive, not recruitingCOVID | ARDS, HumanSweden